Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
12,539 people get MRK articles and Market Currents by email alert.
Get email alerts on MRK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (Wed, 6:29PM)
-
-
-
-
-
-
-
-
Merck's Liptruzet: A Cause For Shame?Derek Lowe • Thu, May 9 -
-
-
-
-
-
-
-
-
Merck's Liptruzet: A Cause For Shame?Derek Lowe • Thu, May 9
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call TranscriptFri, Apr 27, 2012
-
Merck & Co. Inc. - Special CallThu, Nov 10, 2011
-
Merck & Co.'s CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Merck & Co.'s CEO Discusses Q2 2011 Results - Earnings Call TranscriptFri, Jul 29, 2011
-
Merck & Co.'s CEO Discusses Q1 2011 Results - Earnings Call TranscriptFri, Apr 29, 2011
-
Merck CEO Discusses Q3 2010 Results - Earnings Call TranscriptFri, Oct 29, 2010
-
Merck & Co. Q2 2010 Earnings Call TranscriptFri, Jul 30, 2010
-
Merck & Co. Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Merck & Co., Inc. Q4 2009 Earnings Call TranscriptTue, Feb 16, 2010
-
Merck & Co., Inc. Q3 2009 Earnings Call TranscriptThu, Oct 22, 2009
-
Merck & Co. Inc. Q2 2009 Earnings Call TranscriptTue, Jul 21, 2009
-
Merck F1Q09 Earnings Call TranscriptTue, Apr 21, 2009
-
Merck & Co. Q4 2008 Earnings Call TranscriptTue, Feb 3, 2009
-
Business Wire (Wed, 6:29PM)
-
at CNBC.com (May 6, 2013)
-
at CNBC.com (May 2, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at Fox Business (May 1, 2013)
-
at Fox Business (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at Fox Business (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
-
at Fox Business (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at CNBC.com (May 1, 2013)
-
at MarketWatch.com (May 1, 2013)
MRK vs. ETF Alternatives
Company Description
On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation (“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger, Schering-Plough acquired all of the shares of Old Merck, which became a wholly-owned subsidiary of Schering-Plough... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, April 2, 7:05 PM Citi strategists tweak the criteria for their top dividend-paying stock picks, lowering the standard for dividend yield while adding a new filter for dividend momentum “to give more emphasis on dividend safety and growth." The full list: MO, AEP, T, AVB, BMY, ED, D, DD, DUK, INTC, KMB, KRFT, LLY, MCD, MRK, MSFT, NU, NOC, OXY, PFE, PM, RTN, SRE, SO, SYY, XEL. 5 Comments [Quick Ideas]
- Wednesday, March 27, 10:30 AM Merck (MRK -0.7%) says that the Biologics License Application for its investigational Timothy grass pollen allergy tablet has been accepted for review by the FDA. The tablet provides an alternative to shots for one of the most common seasonal allergic maladies, and is supported by extensive data from Phase III testing, which included a long-term, multi-season trial. Earlier this month, the company also submitted a similar application for its investigational ragweed pollen AIT. Comment! [Healthcare]
-
Monday, March 25, 5:29 AM
The Supreme Court is due to hear a "pay for delay" a case today over whether it's legal for drug companies to pay generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The case is the FTC vs Actavis (ACT) and involves Abbott Labs' (ABT) AndroGel testosterone treatment. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation.
7 Comments [Healthcare, Top Stories] - Friday, March 15, 3:08 PM Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation. Comment! [Healthcare, On the Move, Earnings]
- Thursday, March 14, 5:48 PM The FDA is reviewing data on a certain class of diabetes drugs which it says might lead to precancerous changes in the pancreas. The drugs may include Eli Lilly's (LLY) Tradjenta, Merck's (MRK) Januvia, Novo Nordisk's (NVO) Victoza, and Bristol-Myers Squibb's (BMY) Byetta. Labels on the drugs already warn of increased potential for pancreatitis, which is the inflamation of the pancreas. The precancerous changes are new, and would affect future labeling. 4 Comments [Healthcare]
- Wednesday, March 13, 8:56 AM Luminex (LMNX) signs a deal to develop a diagnostic device that will help screen patients for recruitment into Merck's (MRK) clinical trials for MK-8931, its lead investigational candidate for Alzheimer's disease (AD). (PR) Comment! [Healthcare]
- Tuesday, March 12, 8:30 AM Merck (MRK +3.3%) says that the Data Safety Monitoring Board will allow the company to continue with its large-scale trial of its blockbuster Vytorin cholesterol drug, indicating that no safety issues have come up. Some analysts had hoped that the trial would already have demonstrated Vytorin's effectiveness and so could be halted. Alas, the study will continue until September 2014. (PR) Comment! [Healthcare, On the Move]
- Sunday, March 10, 5:00 AM With companies looking to avoid paying taxes on their profits, 83 of the largest firms kept $1.46T overseas in 2012, up 14.4% from the previous year, Bloomberg calculates. GE (GE) again had the most with $108B held offshore, up from $102B in 2011; Pfizer was second with $73B, after which came Microsoft (MSFT), Merck (MRK), Johnson & Johnson (JNJ) and IBM (IBM). 73 Comments [U.S. Economy, Healthcare, Tech, Consumer, Financials]
- Sunday, March 10, 4:24 AM Negative results from a major study of Merck's (MRK) cholesterol drug Tredaptive could spell the end of sales of AbbVie's (ABBV) Niaspan, which is an extended-release form of the niacin vitamin that sold $911M in 2012. Niacin is used in Tredaptive along with Merk's laropiprant; Tredaptive failed to reduce strokes, deaths and heart attacks in patients with vascular diseases but did cause increased side effects. (PR) Comment! [Healthcare, Top Stories]
- Monday, March 4, 11:49 AM Bank of America Merrill Lynch makes a couple valuation calls in healthcare this morning, upping Merck (MRK +1.2%) to Buy on optimism over its osteoporosis drug, and moving to Neutral on Bristol-Myers (BMY -0.9%) due to its limited total-return potential. 1 Comment [Healthcare, On the Move]
- Monday, March 4, 9:50 AM Shares in GSK (GSK -0.6%), Pfizer (PFE +0.3%) and Abbott (ABT +0.2%) show little reaction to news that lamivudine and zidovudine, which they sell in a JV, helped cure a 2/12 year old infant of HIV. Other firms that develop HIV treatments, including Merck (MRK +0.4%), J&J (JNJ +0.35%) and Gilead (GILD +0.3%), also don't seem too impressed. Comment! [Healthcare]
- Tuesday, February 26, 3:56 PM Merck & Co., Inc. (MRK) declares $0.43/share quarterly dividend, in line with previous. Forward yield 4.07%. For shareholders of record Mar. 15. Payable Apr. 05. Ex-div date Mar. 13. (PR) Comment! [Dividends]
- Tuesday, February 26, 1:58 PM Diabetes drugs sold by Merck & Co. (MRK -0.7%) and Bristol-Myers Squibb Co. (BMY +0.1%) may double a user’s risk of developing an inflammation of the pancreas linked to cancer and kidney failure, according to a recent study in the journal JAMA Internal Medicine. Analysis of insurance records indicate that patients hospitalized with pancreatitis were twice as likely to be taking Januvia, MRK’s top-selling drug, or BMY’s Byetta, than a control group of diabetics who didn’t have pancreatitis. Both drugs increase GLP-1, a hormone that stimulates insulin production from the pancreas. Comment! [Healthcare]
- Tuesday, February 26, 9:51 AM Merck's (MRK +0.2%) and Bristol-Myers Squibb's (BMY +0.7%) multi-billion dollar diabetes drugs could double the risks of patients developing pancreatitis, which is an inflammation of the pancreas, a study indicates. Merck's Januvia and Bristol-Myers' Byetta increase GLP-1, a hormone that stimulates the pancreas' insulin output. Other drugs that do the same but weren't in study include Bristol's Onglyza and Novo Nordisk's (NVO) Victoza. Comment! [Healthcare]
- Wednesday, February 13, 9:30 AM Merck (MRK -0.3%) forecasts adjusted EPS of $0.76-$0.78 in Q1, below estimates of $0.86. The guidance includes the impact of Venezuela's 33% devaluation, which the company says will hurt earnings by $0.05 in Q1. "Over the balance of 2013," Merck expects the effect to be $0.02. (PR) Comment! [Earnings, Healthcare]
- Monday, February 11, 3:02 PM A genetically modified smallpox vaccine has been shown to shrink tumors in liver cancer patients and extends survival more than a year, a recent study found. The therapy, from closely held Jennerex, is called JX-594, or Pexa-Vec, and is currently being tested in people with advanced hepatocellular carcinoma. Treatment options for this advanced type of cancer are limited, and San Francisco-based Jennerex is competing with drug behemoths such as Amgen (AMGN -1.5%) and Merck (MRK +0.4%) in the space, as well as others such as Oncolytics Biotech (ONCY -5%) and Dendreon (DNDN -3.3%). 6 Comments
-
- View all 1 replies
-
-
- View all 2 replies
-
-
Chines33: Almost reshorted it on the close but will wait to see what happens at open.
-
Dividend Sheet
$AZN $GSK $MRK are the best yielding heathcare stocks with a lower volatility than the market - http://stks.co/cP2U - $JNJ $TEVA - View all 0 replies
-
John Vincent
Stanley Druckenmiller (Duquesne) added US Airways($LCC) & Southern Company($SO) while adding to Merck($MRK): http://bit.ly/Y9NlpH - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 15 replies
-
SKS1586: andyk80: Mr Market is listening to you & following your thought of bounce, with uptick in all the Futures @ this moment.
-
-
- View all 2 replies
-
-
SKS1586: joe kelly - I reduce or remove my positions for creation of CASH. Therefore I leave trades with much less profit than most Investors/Traders
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Jacob Wolinsky
David Tepper Buys MF Global Credit, IRE Subs and More http://bit.ly/tL9zh2 $MF $IRE $PFE $BAC $UNH $MRK - View all 2 replies
-
Ocean Man: That was a good summary you posted earlier. I was surprised by that MF Global buy. -
Jacob Wolinsky: Thanks its outside my circle of competence. CNBC has confirmed it-http://bit.ly/uHZouF. Hunter has a good post-http://bit.ly/vBdYQy
-
- View all 7 replies
-
Michael Stuart: But high FCF with low reported earnings usually means they can support the dividend but are using some earnings cash for other purposes -
Michael Stuart: Basically, FCF is usually a better proxy metric than earnings for whether a firm can support a dividend or not. At least IMHO.
-
Michael Bryant
"Merck speeding up layoffs of many US employees." Big red flag for Merck (MRK). Companies layoff workers because of lack of demand. - View all 3 replies
-
1980XLS: Laying off workers saves $$,and increases efficiency & productivity. Make the remaining ones sweat with the threat of more layoffs, Bullish. -
Michael Bryant: True, but eventually it will hurt the company. Look at MCD after it announced hiring 50,000 workers.